Overall survival
OS rates were 97.0% in the eltrombopag group and 96.0% in the control group at the last follow-up. Two patients (3.0%) died in the eltrombopag group, including one who died at 12 months after diagnosis of SAA without hematologic response; the other patient died of hematopoietic stem cell transplantation (HSCT) complications. Two patients (4.1%) died in the control group, including one who died after 2 years without hematologic response; the other case died of transplantation complications. Totally 10 patients (20.4%) were lost at the end of follow-up in the control group (Table 2). There was no significant difference in OS between the two groups (P=0.999) (Figure 1).